ArticleSensors (Basel, Switzerland)2026
Development of a Low-Cost Portable Exhaled Breath Ammonia Detector for Supplementary Five-Stage CKD Classification Using Embedded Threshold Logic.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Conventional diagnosis of chronic kidney disease (CKD) relies predominantly on invasive blood-based examinations, limiting the scalability of kidney health screening in resource-constrained environments. This study presents embedded engineering framework for non-invasive, breath-based CKD staging framework supported by machine learning and implemented on a low-cost embedded platform. To account for physiological sex differences in baseline creatinine production, estimated glomerular filtration rate (eGFR) values and breath ammonia concentrations were derived from two independent clinical cohorts using sex-specific MDRD equations (incorporating the standard male formula and the 0.742 female correction factor, respectively) and creatinine-BUN conversion models, with male- and female-parameterized algorithms developed in parallel. The resulting feature space was analyzed using four unsupervised clustering approaches to stratify subjects into five clinically meaningful kidney function stages. Stage-specific ammonia thresholds were implemented within an Arduino Nano-based prototype equipped with an MQ-137 gas sensor and OLED display, enabling real-time point-of-care classification. Dataset-level classification accuracy reached 82% for the male algorithm and 92% for the female algorithm. Hospital-based validation on 29 patients (22 male, 7 female) yielded a real-world testing accuracy of 90.5% (20/22) for male patients and 71.4% (5/7) for female patients, a discrepancy largely attributable to the small female sample size. Because the current evaluation lacks healthy control subjects and is constrained by sample size, these empirical results serve primarily to demonstrate hardware-software functional integration and real-world deployment feasibility rather than definitive clinical efficacy. Despite these preliminary, sample-limited clinical datasets, results suggest this approach holds promise as an accessible, non-invasive screening complement to conventional diagnostic pathways, particularly in low-resource healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.